Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.

James Cheng-Chung Wei Tae Hwan KimMitsumasa KishimotoNaoki OgusuHaeyoun JeongShigeto Kobayashinull null

Published in: Annals of the rheumatic diseases (2021)

Brodalumab demonstrated a significant improvement at week 16 in patients with active axSpA. Safety of brodalumab was consistent with that reported in previous global/Japanese psoriasis studies.

Keyphrases

placebo controlled
monoclonal antibody
double blind
disease activity
ankylosing spondylitis
phase ii
phase iii
study protocol
phase ii study
clinical trial
rheumatoid arthritis
systemic lupus erythematosus
squamous cell carcinoma
open label
radiation therapy